Rain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer
September 08, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced non-clinical...
Rain Therapeutics to Present at IASLC 2021 World Conference on Lung Cancer and Participate in Panel Discussion at Citi 16th Annual Biopharma Virtual Conference
September 01, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will be...
Rain Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
August 10, 2021 08:00 ET
|
Rain Therapeutics Inc
First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (“DD”) liposarcoma (“LPS”) Quarter-end cash position of $164.6 million...
Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021
August 03, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial...
Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program
July 20, 2021 08:00 ET
|
Rain Therapeutics Inc
The randomized, multi-center, open-label Phase 3 trial will evaluate the efficacy and safety of milademetan in patients with de-differentiated (DD) liposarcoma (LPS) Multiple patients with...
Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
June 03, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced a master program and a genomic analysis...
Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
June 02, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced a patient referral partnership...
Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 27, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki,...
Rain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress
May 25, 2021 08:00 ET
|
Rain Therapeutics Inc
Completed initial public offering ("IPO") with net proceeds of $121.9 million Key appointments to the leadership team, board of directors and scientific advisory board Planned Phase 3 trial...
Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President
May 20, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Rain...